No ordinary iCRO

Mission

To advance medicine through the provision of precision imaging biomarker insights for the discovery, development and delivery of novel treatments in neurological disease

About IXICO

IXICO is no ordinary iCRO. By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) expertly managing and analysing neurological clinical trials in diseases such as Alzheimer’s, Huntington’s and Parkinson’s, and establishing respected market leadership tackling the most complex biomarker questions in rare neurodegenerative conditions.

Platform

IXICO’s proprietary AI-driven technology platform enables seamless end-to-end clinical trial management, and the sophisticated measurement and analysis of existing and previously inaccessible disease signalling biology. The Platform helps research scientists to make better informed decisions earlier regarding treatment safety and efficacy, patient eligibility and disease progression.

The Company’s technology and scientific expertise is being applied every day across the world. Clients and partners use IXICO for its advanced technology, scientific expertise and service excellence. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.

Platform

The power of neuroimaging

Neuroimaging provides neuroscience clinical researchers with a powerful tool that visualises extraordinary information about the structural, functional and biochemical characteristics of the human brain.

Due to the complexities of therapy-specific biomarker selection, patient recruitment, analysis methodologies and multi-centre logistics, it is often challenging to translate the value of neuroimaging into successful trial outcomes.

IXICO’s combination of advanced technology and therapeutic expertise enables biopharma partners to address these challenges and realise the full power of imaging biomarkers in their CNS clinical trials.

Partnership

IXICO is working with a number of scientific partners to support disease specific collaborations, spanning academic centres, disease-focused charities and the relevant biopharmaceutical industry companies.

Only by working together can we advance treatments for neurological disease.

Leadership Team

Bram Goorden

CHIEF EXECUTIVE OFFICER

Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestle Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.

Appointment to Board:
August 2024

Grant Nash

CHIEF FINANCIAL OFFICER AND CHIEF OPERATING OFFICER

Grant has worked in the life sciences sector for over 20 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this, he qualified as a Chartered Accountant at PwC and was SVP Finance at Evotec, the early stage drug discovery CRO. Grant is a member of the Share Transaction Committee and also acts as Secretary to the Board and its subcommittees.

Appointment to Board:
August 2019

Robin Wolz, PhD

CHIEF SCIENTIFIC OFFICER AND CHIEF MEDICAL OFFICER

Robin has over 15 years of experience in the development of innovative analytics solutions in healthcare with a focus on imaging technology. Prior to IXICO, Robin held different roles at Philips in the Research and Diagnostic X-Ray divisions. Robin holds a PhD in medical imaging and computer science from Imperial College London, focused on early detection of Alzheimer's disease. He is the co-author of more than 100 publications and holds multiple patents in the field of medical imaging and AI data analytics.

Advisors

Lynne Hughes

Senior Therapeutic Advisor

Over 35 years’ experience in clinical research, Lynne is a leading International Clinical trial expert. Having worked at IQVIA as VP/Global Head of CNS Medical Strategy, exclusively focused in neurology, has had oversight of 450 global trials, including 125 AD, 75 PD and 84 MS trials. Is a member of NIA-NIH taskforce for recruitment into AD trials, co-chair of DAVOS taskforce for expediting clinical AD trials, G7 & G20 World Dementia Councils, and senior advisor to Global Alzheimer's Platform foundation (GAP).

Professor Frederik Barkhof

Medical Advisor

Frederik Barkhof is Professor of Neuroradiology at Amsterdam UMC (NL) and at UCL in London (UK). His research interests focus on multiple sclerosis (spinal cord MRI, grey matter, atrophy), ageing (white matter lesions, microbleeds) and dementia (structural, functional, molecular MR and PET). He has (co)authored >1000 papers referenced in PubMed and is listed among 3000 most influential scientists world-wide by Thompson-Reuters. He is the author of the books “Neuroimaging in Dementia” and “Clinical Neuroradiology: the ESNR textbook”.

Board

Mark Warne

Non-executive chair

Mark is Chief Executive Officer of CHEMAI Ltd and is an advisor to Angelini Ventures. He is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team.

Appointment to Board:
September 2016